Acetyl-Histone H3 (Lys56) Antibody

What is Histone H3 Lysine 56 acetylation and why is it significant in epigenetic research?

Histone H3 Lysine 56 acetylation (H3K56ac) is a post-translational modification that occurs on the core domain of histone H3 rather than on its N-terminal tail. This modification is critical for proper packaging of DNA into chromatin during DNA replication and DNA damage repair . Unlike many histone modifications that occur on the N-terminal tails, H3K56 acetylation takes place within the globular domain of the histone and directly affects the interaction between histones and DNA, influencing nucleosome assembly and stability.

The significance of H3K56ac lies in its role in multiple cellular processes:

• Proper chromatin assembly during DNA replication

• DNA damage response and repair pathways

• Transcriptional regulation

• Cell cycle progression

H3K56 acetylation levels are dynamically regulated throughout the cell cycle, typically peaking during S phase and diminishing in G2, making it an important marker for studying cell cycle-dependent chromatin dynamics .

Which enzymes regulate H3K56 acetylation and deacetylation?

H3K56 acetylation is regulated by specific enzymes that add or remove the acetyl group:

In yeast, Rtt109 is the major histone acetyltransferase for Lys56 acetylation . In mammalian cells, CBP and p300 perform this function, particularly in response to DNA damage induced by γ radiation, ultraviolet light, MMS, or hydroxyurea . Following DNA damage, chromatin assembly factor 1 protein (CAF-1) incorporates acetylated histones into chromatin at sites of DNA repair .

What are the key differences between monoclonal and polyclonal anti-H3K56ac antibodies?

Both monoclonal and polyclonal antibodies against H3K56ac are available, each with distinct advantages for different research applications:

For experiments requiring high specificity, monoclonal antibodies like Clone RM179 are preferred as they specifically react to H3K56ac with no cross-reactivity with other acetylated lysines such as K4ac, K9ac, K14ac, K18ac, K23ac, K27ac, K36ac, K79ac, or K122 in histone H3 .

How should I validate the specificity of an H3K56ac antibody?

Proper validation of H3K56ac antibodies is crucial to ensure experimental reliability:

• Peptide competition assays: Use acetylated and non-acetylated synthetic peptides corresponding to the H3K56 region to confirm antibody specificity.

• Western blot validation:

  • Compare acid extracts from cells treated with HDAC inhibitors (e.g., sodium butyrate) versus untreated cells

  • Use recombinant histone H3 as a positive control

  • Verify the expected molecular weight (~15-17 kDa)

• Cross-reactivity testing:

  • Test against peptide arrays containing various histone modifications

  • Confirm no signal with unmodified K56 or other acetylated lysines (K4ac, K9ac, K14ac, etc.)

• Genetic validation:

  • Use cells with mutations in the enzymes responsible for H3K56ac (e.g., CBP/p300 knockdown)

  • Compare with cells overexpressing histone deacetylases like SirT1 or SirT2

• Positive controls:

  • HeLa cells treated with sodium butyrate

  • Cells in S phase of cell cycle

  • Cells exposed to DNA damaging agents

Example from research: Western Blot of acid extracts from HeLa cells treated with sodium butyrate using RM179 at 1 µg/mL showed a clear band of histone H3 acetylated at Lysine 56, confirming antibody specificity .

What are the optimal conditions for Western blotting with H3K56ac antibodies?

For successful Western blot experiments using H3K56ac antibodies, follow these guidelines:

Sample preparation:

• Extract histones using acid extraction methods (e.g., 0.2N HCl)

• Consider using HDAC inhibitors during extraction to preserve acetylation

• Include protease inhibitors and phosphatase inhibitors in all buffers

SDS-PAGE conditions:

• Use 15-18% gels for optimal separation of histones

• Load 5-20 μg of acid-extracted histones per lane

Transfer and blocking:

• Transfer to PVDF membrane at 30V overnight at 4°C for best results

• Block with 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature

Antibody incubation:

• Primary antibody dilutions:

  • Monoclonal: 1-2 μg/mL (approximately 1:500-1:1000 dilution)

  • Polyclonal: 1:500-1:2000 dilution

• Incubate overnight at 4°C with gentle rocking

• Secondary antibody: Anti-rabbit HRP at 1:5000-1:10000 for 1 hour at room temperature

Detection:

• Use ECL or other chemiluminescent detection methods

• Exposure time: Start with 30 seconds and adjust as needed

Expected result:

• A single band at approximately 17 kDa corresponding to acetylated histone H3

How should I optimize ChIP experiments using H3K56ac antibodies?

Chromatin Immunoprecipitation (ChIP) with H3K56ac antibodies requires specific considerations:

Crosslinking and chromatin preparation:

• Standard 1% formaldehyde for 10 minutes at room temperature

• Optimal sonication conditions: 10-30 second pulses to achieve fragments of 200-500 bp

• Verify fragment size by agarose gel electrophoresis

Immunoprecipitation:

• Recommended antibody amount: 2-5 μg per ChIP reaction

• Pre-clear chromatin with protein A/G beads before adding antibody

• Incubate antibody-chromatin mixture overnight at 4°C with rotation

• Use IgG as negative control and anti-total H3 antibody as positive control

Washing and elution:

• Perform stringent washing steps to reduce background

• Elute chromatin at 65°C in elution buffer containing SDS

• Reverse crosslinks overnight at 65°C

Controls to include:

• Input sample (typically 5-10% of starting chromatin)

• IgG negative control

• Total H3 antibody as positive control for normalization

• Known H3K56ac-enriched genomic regions as positive control loci

For ChIP-sequencing applications, H3K56ac antibodies have been validated to identify regions associated with active gene transcription and replication origins .

How can I use H3K56ac antibodies in immunocytochemistry and immunohistochemistry studies?

For successful ICC/IHC experiments with H3K56ac antibodies:

Cell/tissue preparation:

• Fix cells with 4% paraformaldehyde for 15 minutes at room temperature

• For tissue sections, use standard fixation protocols followed by antigen retrieval

• Permeabilize with 0.1-0.5% Triton X-100 for 10 minutes

Blocking and antibody incubation:

• Block with 5% normal goat serum in PBS for 1 hour at room temperature

• Primary antibody dilutions:

  • ICC: 0.5-2 μg/mL

  • IHC: 1-10 μg/mL

• Incubate overnight at 4°C in a humidified chamber

Detection and visualization:

• Use fluorescent secondary antibodies for co-localization studies

• For brightfield IHC, use HRP-conjugated secondary antibodies and DAB substrate

• Include DAPI counterstain to visualize nuclei

Expected results:

• Nuclear staining pattern

• Increased signal in proliferating cells (S-phase)

• Enhanced staining in cells treated with HDAC inhibitors

Example from research: Immunocytochemistry of HeLa cells treated with sodium butyrate using Acetyl-Histone H3 (Lys56) Rabbit mAb RM179 showed clear nuclear staining, which can be visualized alongside actin filaments labeled with fluorescein phalloidin .

How does H3K56 acetylation vary during the cell cycle and what are its implications?

H3K56 acetylation shows distinct patterns throughout the cell cycle, which has important implications for chromatin dynamics:

This cell cycle-dependent pattern is critical because:

• H3K56ac occurs normally during S phase, corresponding with DNA replication timing

• The modification disappears in G2 under normal conditions through the action of histone deacetylases

• In the presence of DNA damage, H3K56ac persists beyond S phase, signaling the need for DNA repair

• This dynamic regulation is essential for proper nucleosome assembly during replication and repair

Researchers can use this knowledge to interpret H3K56ac patterns in experimental data. For example, cells arrested in different cell cycle phases will show varying levels of H3K56ac, and this can be used as a marker for cell cycle position or replication stress.

What is the relationship between H3K56 acetylation and the DNA damage response?

H3K56 acetylation plays a crucial role in the DNA damage response pathway:

• Induction after DNA damage: H3K56ac levels increase in response to various DNA damaging agents including γ radiation, ultraviolet light, MMS, and hydroxyurea

• Mechanism of action:

  • CBP and p300 acetyltransferases are activated following DNA damage

  • H3K56ac facilitates nucleosome assembly at sites of DNA repair

  • Chromatin assembly factor 1 (CAF-1) specifically incorporates H3K56-acetylated histones into chromatin at repair sites

• Persistence of the mark: While H3K56ac normally disappears in G2, it persists when DNA damage is present, serving as a signal for ongoing repair processes

• Functional importance:

  • Mutants lacking H3K56ac show hypersensitivity to DNA-damaging agents

  • The modification helps maintain genomic stability by facilitating proper repair

  • Defects in H3K56ac regulation can lead to genomic instability and cancer

Research has shown that histone H3 Lys56 acetylation levels are high in multiple types of cancer, and acetylation levels directly correlate with cellular dedifferentiation and tumorigenicity , suggesting this modification could serve as a biomarker or therapeutic target.

How does H3K56 acetylation compare to other histone H3 modifications?

H3K56 acetylation has distinct characteristics compared to other histone H3 modifications:

Key distinctions include:

• Location: Unlike most well-studied histone modifications that occur on the N-terminal tails, H3K56ac occurs within the globular domain of histone H3, directly at the DNA entry/exit point of the nucleosome

• Structural impact: Due to its location, H3K56ac directly affects DNA-histone binding, potentially loosening the DNA wrap around the histone octamer

• Functional specificity: While many acetylation marks (H3K9ac, H3K14ac, H3K27ac) are broadly associated with active transcription, H3K56ac has more specialized roles in replication, repair, and nucleosome assembly

• Evolutionary conservation: The machinery regulating H3K56ac is highly conserved from yeast to humans, though with some differences in the specific enzymes involved

Understanding these differences is crucial for interpreting experimental data involving multiple histone modifications.

Why might I see weak or no signal in my H3K56ac Western blot?

Several factors can contribute to weak or absent H3K56ac signals in Western blot experiments:

• Low abundance of modification:

  • H3K56ac levels may be naturally low in your samples, especially if cells are in G1 or G2/M phases

  • Solution: Treat cells with HDAC inhibitors like sodium butyrate to increase acetylation levels

• Loss of modification during sample preparation:

  • Acetylation marks are labile and can be lost during extraction

  • Solution: Add HDAC inhibitors (5-10 mM sodium butyrate or 1 μM TSA) to all extraction buffers

• Antibody sensitivity issues:

  • Different antibody clones have varying sensitivities

  • Solution: Test multiple antibodies or increase antibody concentration

• Improper histone extraction:

  • Standard protein extraction may not efficiently isolate histones

  • Solution: Use acid extraction methods (0.2N HCl) specifically designed for histones

• Technical Western blot issues:

  • Poor transfer of low molecular weight proteins

  • Solution: Use PVDF membranes and optimize transfer conditions for small proteins

How can I troubleshoot specificity issues with H3K56ac antibodies?

When facing specificity concerns with H3K56ac antibodies:

• Confirm antibody specificity:

  • Perform peptide competition assays with acetylated and non-acetylated peptides

  • Test antibody against multiple histone modifications to ensure it only recognizes H3K56ac

  • Use the RM179 clone which has been shown to have no cross-reactivity with unmodified K56 or other acetylated lysines in histone H3

• Validate with positive and negative controls:

  • Positive control: HeLa cells treated with sodium butyrate

  • Positive control: Recombinant histone H3.3 (acetylated)

  • Negative control: Samples with SIRT1/2 overexpression to reduce H3K56ac

• Check for interfering modifications:

  • Nearby modifications may affect antibody binding

  • Consider using mass spectrometry to characterize all modifications present

• Optimize antibody concentration:

  • Titrate antibody concentration (1-2 μg/mL for Western blot)

  • For ICC/IHC, use 0.5-10 μg/mL depending on sample type

• Consider alternative detection methods:

  • If one application (e.g., Western blot) shows specificity issues, try another (e.g., ChIP or ICC)

  • Some antibody clones perform better in specific applications

The high specificity of monoclonal antibodies like RM179 makes them excellent choices when specificity is a concern, as they have been validated to specifically react with H3K56ac with no cross-reactivity to other acetylated lysines in histone H3 .

What are the best practices for storage and handling of H3K56ac antibodies?

Proper storage and handling are crucial for maintaining antibody performance:

Storage conditions:

• Store at -20°C for long-term storage as recommended by manufacturers

• Most H3K56ac antibodies are stable for 1 year at -20°C from the date of receipt

• Store in smaller aliquots to avoid repeated freeze-thaw cycles

Buffer composition:

• Most H3K56ac antibodies are supplied in specialized buffers:

  • 50% Glycerol/PBS with 1% BSA and 0.09% sodium azide

  • 70 mM Tris (pH 8), 105 mM NaCl, 31 mM glycine, 0.07 mM EDTA, 30% glycerol

• Do not alter the buffer composition as it may affect stability

Handling recommendations:

• Avoid repeated freeze-thaw cycles that can degrade antibody performance

• Thaw antibodies on ice before use

• Centrifuge briefly before opening vials to collect liquid at the bottom

• Use sterile technique when removing aliquots

Working dilutions:

• Prepare working dilutions fresh on the day of the experiment

• Return stock antibody to -20°C immediately after use

• Do not store diluted antibody for extended periods

Following these storage and handling practices will help ensure consistent antibody performance and reproducible experimental results over time.

What are emerging areas of research involving H3K56 acetylation?

Several promising research directions are emerging in the field of H3K56 acetylation:

• Cancer epigenetics: H3K56ac levels are high in multiple types of cancer, and acetylation levels directly correlate with cellular dedifferentiation and tumorigenicity . Future research may focus on:

  • Developing H3K56ac as a diagnostic or prognostic biomarker

  • Targeting the enzymes that regulate H3K56ac for cancer therapy

  • Understanding how H3K56ac contributes to genomic instability in cancer

• Aging and longevity: The sirtuins that deacetylate H3K56 (SirT1, SirT2, SirT6) are implicated in aging processes and longevity . Research questions include:

  • How does H3K56ac change during cellular aging?

  • Can modulation of H3K56ac affect lifespan or healthspan?

  • What is the relationship between caloric restriction, sirtuins, and H3K56ac?

• Stem cell biology: Dynamic histone modifications including H3K56ac may play crucial roles in stem cell identity and differentiation. Future studies might explore:

  • The role of H3K56ac in maintaining pluripotency

  • Changes in H3K56ac during cellular reprogramming

  • Targeting H3K56ac to improve differentiation protocols

• Novel detection technologies: Development of new technologies for studying H3K56ac in single cells or in vivo:

  • Single-cell ChIP-seq methods for H3K56ac

  • Live-cell imaging of H3K56ac dynamics

  • Genome editing to create acetylation-mimetic histone variants

Researchers are likely to combine H3K56ac antibodies with emerging technologies like spatial transcriptomics, single-cell multi-omics, and advanced imaging techniques to gain deeper insights into the biological functions of this important histone modification.

How might therapeutic targeting of H3K56 acetylation be developed?

The therapeutic potential of targeting H3K56 acetylation pathways is an exciting area for future research:

• Cancer therapy approaches:

  • HDAC inhibitors: While broad-spectrum HDAC inhibitors like sodium butyrate affect multiple acetylation sites , developing sirtuin-specific inhibitors might provide more targeted approaches to modulate H3K56ac

  • HAT inhibitors: Targeting CBP/p300 to reduce H3K56 acetylation in cancers where it is aberrantly high

  • Synthetic lethality: Identifying genetic contexts where modulation of H3K56ac is selectively lethal to cancer cells

• DNA damage response modulation:

  • Enhancing DNA repair in degenerative conditions by promoting H3K56ac

  • Sensitizing cancer cells to chemotherapy by inhibiting H3K56ac-dependent repair pathways

  • Using H3K56ac status as a biomarker for DNA damage response capacity

• Delivery challenges and solutions:

  • Developing cell-penetrating antibodies against H3K56ac for diagnostic imaging

  • Creating small molecule probes that specifically recognize H3K56ac

  • Using targeted nanoparticles to deliver H3K56ac-modulating compounds to specific tissues